X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (84) 84
humans (83) 83
oncology (76) 76
female (51) 51
male (49) 49
middle aged (46) 46
aged (43) 43
antineoplastic combined chemotherapy protocols - therapeutic use (41) 41
adult (40) 40
chemotherapy (37) 37
colorectal neoplasms - drug therapy (33) 33
colorectal cancer (32) 32
cancer (28) 28
fluorouracil - administration & dosage (28) 28
treatment outcome (25) 25
colorectal neoplasms - pathology (23) 23
prognosis (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
camptothecin - analogs & derivatives (21) 21
leucovorin - administration & dosage (21) 21
cetuximab (20) 20
oxaliplatin (20) 20
1st-line treatment (18) 18
aged, 80 and over (18) 18
care and treatment (18) 18
disease-free survival (17) 17
leucovorin (17) 17
fluorouracil (16) 16
research (16) 16
5-fluorouracil (15) 15
irinotecan (15) 15
metastasis (15) 15
adolescent (14) 14
camptothecin - administration & dosage (14) 14
fluorouracil - adverse effects (14) 14
neoplasm metastasis (14) 14
young adult (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
drug therapy (12) 12
folinic acid (12) 12
hematology (12) 12
hematology, oncology and palliative medicine (12) 12
kaplan-meier estimate (12) 12
survival rate (12) 12
colorectal neoplasms - mortality (11) 11
leucovorin - adverse effects (11) 11
mutation (11) 11
panitumumab (11) 11
survival analysis (11) 11
abridged index medicus (10) 10
antibodies, monoclonal, humanized (10) 10
antineoplastic agents - therapeutic use (10) 10
bevacizumab (10) 10
chemotherapy, adjuvant (10) 10
drug administration schedule (10) 10
fluorouracil - therapeutic use (10) 10
therapy (10) 10
colorectal neoplasms - genetics (9) 9
liver neoplasms - secondary (9) 9
metastatic colorectal cancer (9) 9
prospective studies (9) 9
trial (9) 9
age factors (8) 8
antineoplastic agents (8) 8
camptothecin - adverse effects (8) 8
capecitabine (8) 8
carcinoma (8) 8
clinical trials (8) 8
clinical trials as topic (8) 8
follow-up studies (8) 8
oncology, experimental (8) 8
administration, oral (7) 7
antibodies, monoclonal - administration & dosage (7) 7
antimitotic agents (7) 7
camptothecin - therapeutic use (7) 7
colon-cancer (7) 7
europe (7) 7
expression (7) 7
health aspects (7) 7
infusions, intravenous (7) 7
leukemia, myeloid, acute - genetics (7) 7
leukemia, myeloid, acute - mortality (7) 7
liver metastases (7) 7
medical and health sciences (7) 7
medicin och hälsovetenskap (7) 7
medicine & public health (7) 7
neoplasm staging (7) 7
phase-iii trial (7) 7
proto-oncogene proteins - genetics (7) 7
randomized controlled trials as topic (7) 7
ras proteins - genetics (7) 7
receptor, epidermal growth factor - antagonists & inhibitors (7) 7
survival (7) 7
tumors (7) 7
analysis (6) 6
antibodies, monoclonal - adverse effects (6) 6
antibodies, monoclonal - therapeutic use (6) 6
cancer therapies (6) 6
continuous-infusion (6) 6
deoxycytidine - analogs & derivatives (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Colorectal Cancer, ISSN 1533-0028, 03/2018, Volume 17, Issue 1, pp. 50 - 57.e8
There is a need to identify patients who may benefit from particular treatments. We investigated prognosis in 915 patients with mCRC from 2 phase III trials of... 
Chemotherapy | Prognosis | Overall survival | Progression-free survival | Panitumumab | 1ST-LINE TREATMENT | LEUCOVORIN | PHASE-III | OPEN-LABEL | FOLFIRI PLUS BEVACIZUMAB | FLUOROURACIL | CETUXIMAB | ONCOLOGY | 2ND-LINE TREATMENT | Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2009, Volume 360, Issue 14, pp. 1408 - 1417
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9897, pp. 1021 - 1028
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Summary Background Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | BEVACIZUMAB | OXALIPLATIN | FLUOROURACIL | HEPATIC RESECTION | CANCER | CARCINOMA | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
BMC cancer, ISSN 1471-2407, 2012, Volume 12, Issue 1, pp. 438 - 438
Background: Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal... 
IRINOTECAN FOLFIRI | MANAGEMENT | EFFICACY | Panitumumab | Colorectal cancer | Tolerability | FLUOROURACIL | TUMORS | CHEMOTHERAPY | Quality of life | TRIAL | EGFR INHIBITORS | CETUXIMAB | ONCOLOGY | KRAS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Skin Diseases - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Skin Diseases - pathology | Young Adult | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Skin - pathology | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Skin Diseases - chemically induced | Mutation - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Aged | Colorectal Neoplasms - pathology | Genes, ras | Skin - drug effects | Usage | Patient outcomes | Analysis | Dosage and administration | Research | Drug therapy | Antimitotic agents | Cancer patients | Care and treatment | Chemotherapy | Epidermal growth factor | Monoclonal antibodies | Skin | Metastasis | Antineoplastic agents | Patient compliance | Cancer | Biotechnology industry | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 12, pp. 1350 - 1357
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2012, Volume 49, Issue 2, pp. 439 - 448
Abstract Background In the CRYSTAL study adding cetuximab to first-line FOLFIRI significantly improved outcome in patients with KRAS wild-type metastatic... 
Hematology, Oncology and Palliative Medicine | KRAS wild-type | Cetuximab | Metastatic colorectal cancer | FOLFIRI | Quality of life | HEAD | BEVACIZUMAB | OXALIPLATIN | CHEMOTHERAPY | BREAST-CANCER | TRIAL | PANITUMUMAB | ONCOLOGY | LINE | PREDICTS SURVIVAL | NECK | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Young Adult | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Surveys and Questionnaires | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Colorectal Neoplasms - enzymology | Proto-Oncogene Proteins - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Quality of Life | Aged | Colorectal Neoplasms - pathology | Antimitotic agents | Care and treatment | Oncology, Experimental | Colorectal cancer | Leucovorin | Metastasis | Research | Antineoplastic agents | Cancer | Index Medicus
Journal Article